Maximum is 150 mg phenylpropanolamine or 2.4 grams of guaifenesin/day.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Phenylpropanolamine is eliminated by the kidney and may accumulate in patients with renal dysfunction. Patients with renal dysfunction should be monitored for signs and symptoms of toxicity when using phenylpropanolamine.

Precautions

Check concentration.

Dialysis

Data not available

Other Comments

In November 2000, the Food and Drug Administration (FDA), in response to reports of increased risk of hemorrhagic stroke, requested that all drug companies discontinue marketing products containing phenylpropanolamine.